Back From The Brink: Genmab's Arzerra Win's CLL Approval And Cash From Partner GSK
This article was originally published in The Pink Sheet Daily
Executive Summary
Danish biotech set back by an earlier failure in non-Hodgkin's lymphoma plans new studies with a $23 million milestone payment from partner GSK.